Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) Shares Outstanding (Diluted Average) (2022 - 2025)

Historic Shares Outstanding (Diluted Average) for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $41.5 million.

  • Entrada Therapeutics' Shares Outstanding (Diluted Average) rose 205.01% to $41.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.5 million, marking a year-over-year increase of 205.01%. This contributed to the annual value of $39.0 million for FY2024, which is 1801.15% up from last year.
  • Per Entrada Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $41.5 million for Q3 2025, which was up 205.01% from $41.3 million recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Shares Outstanding (Diluted Average) ranged from a high of $41.5 million in Q3 2025 and a low of $31.2 million during Q1 2022
  • Moreover, its 4-year median value for Shares Outstanding (Diluted Average) was $34.8 million (2023), whereas its average is $35.5 million.
  • Data for Entrada Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY increase of 1805.88% (in 2025) and a maximum YoY decrease of 205.01% (in 2025) over the last 5 years.
  • Over the past 4 years, Entrada Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $31.3 million in 2022, then rose by 5.61% to $33.1 million in 2023, then rose by 18.01% to $39.0 million in 2024, then rose by 6.31% to $41.5 million in 2025.
  • Its last three reported values are $41.5 million in Q3 2025, $41.3 million for Q2 2025, and $41.1 million during Q1 2025.